Urinary incontinence, or leakage of urine, is a very common condition for women of all ages, ethnicities and backgrounds.

Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Urinary incontinence, defined as the involuntary loss of urine, is common, particularly in women. Despite its significant consequences, it is often under recognized and under treated. In one ...

In today’s fast-paced world, many women are turning a blind eye to a common yet often unspoken issue: urinary incontinence.

Overactive bladder (OAB) is characterized by the storage ... outcomes in the elderly are not as robust as those in younger women. In addition, adverse events related to surgery are also more ...

The study evaluated the prevalence of NE, lower urinary tract symptoms (LUTS), urodynamic factors, and social factors in OAB-wet patient. Over three years, adult women with urgency urinary ...

The Oxytrol for Women (oxybutynin) patch is available without a prescription to treat those with an overactive bladder, which can cause incontinence problems and make women run to the bathroom ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...